Breaking New Ground in Allergy Research: Precision Medicine and Global Collaboration Drive a $30 Billion Market

The Global Burden of Allergic Diseases

Allergies have emerged as a significant global health challenge. The World Health Organization (WHO) estimates that 20% to 30% of the global population is affected by conditions such as rhinitis, asthma, food allergies, or dermatological allergies. According to the World Allergy Organization (WAO), approximately 300 million individuals worldwide suffer from asthma, while 200 to 250 million may have food allergies. Additionally, one in ten people exhibits sensitivity to drug allergies, and 400 million are impacted by rhinitis. Compounding this issue, these conditions often co-occur, with rising cases of multiple allergies, food sensitivities, or severe asthma placing increasing strain on healthcare systems and societies. These disorders not only diminish quality of life but also impose substantial medical and economic burdens. Post-pandemic, there has been a surge in demand for research into immunological issues, positioning allergy etiology as a critical area of focus. Recent analyses from the Global Burden of Diseases (GBD) Study 2019 reveal that in 2019, there were 262 million cases of asthma (95% uncertainty interval [UI]: 224–309 million) and 171 million cases of atopic dermatitis (95% UI: 165–178 million) globally. Age-standardized prevalence rates stood at 3416 per 100,000 (95% UI: 2899–4066) for asthma—a 24.1% decrease from 1990—and 2277 per 100,000 (95% UI: 2192–2369) for atopic dermatitis—a 4.3% decrease. These trends highlight an increase in total cases but a decline in age-standardized rates, influenced by factors like socio-demographic index (SDI), age, and geography (Shin et al., 2023).

Fig 1.Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories (Allergy. 2023; 78(8): 2232–2254.)

Mechanisms of Allergic Sensitization

Allergic reactions typically arise from an exaggerated immune response to specific triggers, predominantly through IgE-mediated Type I hypersensitivity. Upon initial exposure to an allergen, the immune system produces allergen-specific IgE antibodies, which bind to mast cells and basophils. Subsequent encounters with the same allergen prompt these cells to release mediators such as histamine, leukotrienes, and prostaglandins, triggering inflammation, vasodilation, and tissue swelling. In respiratory allergies, this may manifest as bronchial constriction and mucus hypersecretion, while food or insect allergies can lead to anaphylaxis. Research indicates that genetic predispositions, environmental factors (e.g., pollution and reduced microbial exposure), and early-life experiences (e.g., antibiotic use) enhance Th2 cell activity, increasing susceptibility to allergies. For instance, studies on Aedes aegypti mosquito bites in mice have demonstrated a mixed immune response, with elevated Th2 cells and cytokines like IL-4, IL-5, and IL-13, alongside Th1- and Th2-related antibodies in serum (Barros et al., 2016).

Fig 2.Type 1 allergic reactions promote protective antigen avoidance behaviour via IgE armed mast cells(Signal Transduction and Targeted Therapy (2023) 8:446)

Common Allergen Triggers

Allergens are categorized into inhaled, food-based, and contact types. The table below lists common allergens, grouped by species, to provide insight into their origins. The chart below visualizes the distribution of these allergens.

Fig 3 Allergen Distribution Chart.(Geneva: WHO; 2023.)

Recent Advances in Allergy Research

2025 has proven to be a pivotal year for allergy research. Biologics are increasingly replacing corticosteroids, transforming patient outcomes, while oral immunotherapy (OIT) has become faster and safer. Multi-allergen therapies are also gaining traction. Research from the University of North Carolina School of Medicine highlights the efficacy of omalizumab, an FDA-approved biologic, which outperforms OIT in reducing the risk of reactions to allergens like peanuts. This groundbreaking UNC study, featured in National Geographic, underscores omalizumab’s potential in mitigating food allergy risks. The 2025 European Academy of Allergy and Clinical Immunology Annual Meeting addressed new developments in rhinitis-related conditions, while webinars explored future food allergy treatment options, including cutting-edge innovations. The CFAAR 2025 Food Allergy Summit advanced policy, education, and research collaboration, and a University of Michigan conference delved into novel therapies, with some experts hinting at the possibility of a cure. Scientific awards are further incentivizing clinically relevant research, with notable progress in nut allergy treatments and sesame allergy diagnostics. These advancements signal a promising future for precision medicine and innovative therapies.

Fig  4.Successful Consumption of a Prespecified Threshold Dose at Week 16.(New England Journal of Medicine. 2024;390:1234–1245.)

For researchers investigating IgE-mediated immune responses, allergen structures, or novel diagnostic and therapeutic approaches, abinScience is committed to delivering high-quality recombinant allergen proteins and specific antibodies to accelerate your work. Whether for basic research or clinical applications, our products are designed to meet your needs. Our recombinant proteins are optimized for ELISA, Western Blot, and immunogenicity studies, while our antibodies support immunohistochemistry and flow cytometry.

Recombinant Protein Products

Antibody Products

Note: All products undergo rigorous quality control, with purity exceeding 95% and guaranteed bioactivity.

Research Trends and Market Opportunities in Allergy

Allergy research is advancing toward precision medicine and immunotherapy, with innovations such as CAR-T cell therapies for allergies and the development of nanobodies. Our nanobodies, such as SAA1357 for Bet v 1, are well-suited to support these cutting-edge experiments. The market outlook is equally promising, with the global allergy market projected to reach $30 billion by 2030, driven by growing demand for diagnostic and therapeutic tools. The WAO has identified severe and complex allergies as a critical unmet global health need, advocating for early diagnosis and prevention through education, research, and outreach in collaboration with iCAALL. This initiative includes developing communication tools for experts, clinicians, and the public to enhance global awareness of allergies and asthma (Pawankar, 2012).

For researchers, partnering with abinScience offers access to customized products and technical support. For distributors, this presents an opportunity to expand allergy product portfolios. Act now to collaborate and drive allergy research forward!

About abinScience

abinScience is a leading biotechnology company specializing in allergy, immunology, and diagnostics, offering high-quality recombinant proteins, antibodies, and kits.

References

1.Barros, M. S., Gomes, E., Gueroni, D. I., et al. (2016). Exposure to Aedes aegypti bites induces a mixed-type allergic response following salivary antigens challenge in mice. PLoS ONE, 11(5), e0155454. https://doi.org/10.1371/journal.pone.0155454
2.Market Research Future. (2024). Allergy Diagnostic Market Report 2024. Market Research Future. https://www.marketresearchfuture.com/reports/allergy-diagnostic-market-42041
3.Market Research Future. (2024). Allergy Treatment Market – Size, Growth, Trends, Forecast 2024–2035. Market Research Future. https://www.marketresearchfuture.com/reports/allergy-treatment-market-11156
4.Pawankar, R. (2012). The unmet global health need of severe and complex allergies: Meeting the challenge. World Allergy Organization Journal, 5(2), 20-21. https://doi.org/10.1097/WOX.0b013e31824a5552
5.Shin, Y. H., Hwang, J., Kwon, R., Lee, S. W., Kim, M. S., GBD 2019 Allergic Disorders Collaborators, Shin, J. I., & Yon, D. K. (2023). Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Allergy, 78(8), 2232-2254. https://doi.org/10.1111/all.15807
6.World Health Organization & Food and Agriculture Organization of the United Nations. (2023). Risk assessment of food allergens – Part 3: Review and establish precautionary labelling in foods of the priority allergens. Geneva: WHO. https://iris.who.int/handle/10665/369379
7.World Health Organization & Food and Agriculture Organization of the United Nations. (2024). Risk assessment of food allergens – Part 4. Geneva: WHO. https://iris.who.int/handle/10665/376100